ARTICLE | Top Story
BMY to re-submit Vanlev NDA
September 25, 2001 7:00 AM UTC
Bristol-Myers Squibb (BMY) plans to re-submit by year end an NDA to the FDA for its Vanlev omapatrilat, a vasopeptidase inhibitor, to treat hypertension. Last year, BMY withdrew the NDA in response to...